<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844194</url>
  </required_header>
  <id_info>
    <org_study_id>1208.34</org_study_id>
    <secondary_id>2008-002731-32</secondary_id>
    <nct_id>NCT00844194</nct_id>
  </id_info>
  <brief_title>Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder</brief_title>
  <official_title>A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP)
      patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given
      as 60 mg to 120 mg once daily (QD) leads to a clinically relevant improvement as measured by
      the change in Brief Pain Inventory (BPI) 24 hours average interference score from baseline to
      after 12 weeks. A clinically relevant improvement will be demonstrated if the confidence
      interval for the mean change from baseline does not lie above the clinically relevant change
      of -1.35. If statistically significant results are obtained for the DPNP patients with MDD,
      then the same evaluation will be performed for the DPNP patients without MDD in another
      confirmatory analysis.

      As secondary objectives the study will compare the two groups (MDD+/MDD-) regarding efficacy
      of duloxetine on BPI severity scales, the distribution of different percentages of pain
      reduction among the patient population, and the patients and physicians impressions of
      severity and improvement of pain.

      The study will also compare treatment outcomes regarding patient-relevant functionality and
      quality of life (QoL) between the two groups (MDD+/MDD-) by evaluating each single BPI
      interference item, the Short Form 12 (SF-12) Health Questionnaire and the West Haven
      Multidimensional Pain Inventory (MPI).

      As a third group of secondary objectives the efficacy of duloxetine of the psychological
      symptoms (e.g. depression) of DPNP patients with or without depression will be assessed using
      the Hamilton depression scale, the Beck Depression Inventory-II and the hospital Anxiety and
      Depression Scale.

      Further the effect of duloxetine treatment on fasting blood glucose (FBG) and hemoglobin A1c
      (HbA1c) will be evaluated.

      To monitor safety and tolerability, treatment discontinuation rates, treatment emergent
      adverse events, change in vital signs, laboratory results and suicidal thoughts will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPI Worst Pain During Treatment From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Worst Pain (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Worst Pain (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Least Pain (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Least Pain During Treatment (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Least Pain (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Pain (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Pain During Treatment (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Pain (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Reduction in BPI Average Pain at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Reduction in BPI Average Pain at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Reduction in BPI Average Pain at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain During Treatment (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the pain at week 2 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the pain at week 6 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain During Treatment (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the pain at week 12 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Mood (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Mood (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Mood (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression - Improvement (PGI-I) at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression - Improvement (PGI-I) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression - Improvement (PGI-I) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS Anxiety Total Score From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS Anxiety Total Score From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS Depression Total Score From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS Depression Total Score From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HADS Depression Total Score From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (not at all strong) to 6 (very strong).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Severity Pain From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Severity Pain From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Severity Pain From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Score From Baseline to Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline reflects the week 2 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Score From Baseline to Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Score From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts by BDI-II at Week 2</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts by BDI-II at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts by BDI-II at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts or Behaviours by HAMD-17 at Week 2</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts or Behaviours by HAMD-17 at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Thoughts or Behaviours by HAMD-17 at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Fasting Blood Glucose From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Ancova analysis controlling for baseline and insulin intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Ancova analysis controlling for baseline and insulin intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Systolic Blood Pressure From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Diastolic Blood Pressure From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pulse Rate From Baseline at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>DPNP with depression (1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (&gt;30% pain reduction after week 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPNP with depression (2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (&lt;30% pain reduction after week 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPNP without depression (1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (&gt;30% pain reduction after week 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPNP without depression (2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (&lt;30% pain reduction after week 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60 mg QD</intervention_name>
    <description>given to (1) all patients week 2-6; (2) all responders of both arms week 7-12</description>
    <arm_group_label>DPNP without depression (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60 mg QD</intervention_name>
    <description>given to (1) all patients week 2-6; (2) all responders of both arms week 7-12</description>
    <arm_group_label>DPNP with depression (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 30 mg QD</intervention_name>
    <description>given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)</description>
    <arm_group_label>DPNP without depression (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 30 mg QD</intervention_name>
    <description>given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)</description>
    <arm_group_label>DPNP with depression (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 90 mg QD</intervention_name>
    <description>given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD</description>
    <arm_group_label>DPNP with depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 90 mg QD</intervention_name>
    <description>given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD</description>
    <arm_group_label>DPNP without depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60 mg QD</intervention_name>
    <description>given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down</description>
    <arm_group_label>DPNP without depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60 mg QD</intervention_name>
    <description>given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down</description>
    <arm_group_label>DPNP with depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 120 mg QD</intervention_name>
    <description>given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated</description>
    <arm_group_label>DPNP without depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 30 mg QD</intervention_name>
    <description>given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)</description>
    <arm_group_label>DPNP without depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 30 mg QD</intervention_name>
    <description>given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)</description>
    <arm_group_label>DPNP with depression (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 120 mg QD</intervention_name>
    <description>given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated</description>
    <arm_group_label>DPNP with depression (2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Present with pain due to bilateral peripheral neuropathy (according to International
             Statistical Classification of Diseases and Related Health Problems 10 (ICD 10).

          2. To qualify for the MDD+ cohort, patients need to meet the ICD-10 criteria for MDD.
             Furthermore, Hamilton rating scale for depression 17 (HAMD-17) scores need to match
             with the ICD-10 criteria for qualification of the MDD+ or MDD- groups.

          3. Male or female outpatients at least 18 years of age.

          4. Females with child bearing potential must test negative for a serum pregnancy test at
             Visit 1. Females of child-bearing potential (not surgically sterilized and between
             menarche and 1 year post-menopause) must agree to utilize medically acceptable and
             reliable means of birth control as determined by the investigator during the study and
             for 1 month following the last dose of the study. Examples of reliable methods include
             use of oral contraceptives or Depo-Clinovir Contraceptive Injection (sterile
             medroxyprogesterone acetate suspension, Pharmacia), partner with vasectomy, diaphragms
             with contraceptive jelly, cervical caps with contraceptive jelly, condoms with
             contraceptive foam, or intrauterine devices. Women who are pregnant or breast-feeding
             may not participate in the study.

          5. Educational level and degree of understanding such that they can communicate
             intelligibly with the investigator and study coordinator.

          6. Judged to be reliable and agrees to keep all appointments for clinic visits, tests,
             and procedures required by the protocol.

        Exclusion criteria:

          1. Have already a diagnosis of Depression and are currently treated with an
             antidepressant medication for depression, when entering the study.

          2. Suffer from pain that cannot be clearly differentiated from or conditions that
             interfere with the assessment of DPNPain.

          3. Had a historical exposure to drugs known to cause neuropathy, that could have been
             responsible for neuropathy.

          4. Have previously been treated with duloxetine (for DPNP or MDD)

          5. Are judged to be at suicidal risk by the clinical investigator or as defined by a
             score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II).

          6. Had a history of substance abuse or dependence within the past year, excluding
             nicotine and caffeine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1208.34.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Achim bei Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baesweiler</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hattingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelkheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Limburgerhof</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mnster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stuhr</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterhaching</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1208.34.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <results_first_submitted>June 7, 2011</results_first_submitted>
  <results_first_submitted_qc>September 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2011</results_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Without Major Depressive Disorder (MDD-)</title>
          <description>Patients with diabetic polyneuropathy and no depression</description>
        </group>
        <group group_id="P2">
          <title>With Major Depressive Disorder (MDD+)</title>
          <description>Patients with diabetic polyneuropathy and depression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients receiving at least one dose of study medication (TS).</population>
      <group_list>
        <group group_id="B1">
          <title>Without Major Depressive Disorder (MDD-)</title>
          <description>Patients with diabetic polyneuropathy and no depression</description>
        </group>
        <group group_id="B2">
          <title>With Major Depressive Disorder (MDD+)</title>
          <description>Patients with diabetic polyneuropathy and depression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="10.2"/>
                    <measurement group_id="B2" value="66.6" spread="9.8"/>
                    <measurement group_id="B3" value="67.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.91"/>
                    <measurement group_id="O2" value="-2.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>with last observation carried forward (LOCF)</method_desc>
            <param_type>LSmean</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LSmean</param_type>
            <param_value>-1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.88"/>
                    <measurement group_id="O2" value="-2.0" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BPI Worst Pain During Treatment From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BPI Worst Pain During Treatment From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.27"/>
                    <measurement group_id="O2" value="-1.9" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Worst Pain (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Worst Pain (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.36"/>
                    <measurement group_id="O2" value="-3.3" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Worst Pain (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Worst Pain (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.55"/>
                    <measurement group_id="O2" value="-3.2" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Least Pain (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Least Pain (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.35"/>
                    <measurement group_id="O2" value="-0.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Least Pain During Treatment (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Least Pain During Treatment (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.92"/>
                    <measurement group_id="O2" value="-1.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Least Pain (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Least Pain (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.13"/>
                    <measurement group_id="O2" value="-1.1" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Pain (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Pain (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.87"/>
                    <measurement group_id="O2" value="-1.1" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Pain During Treatment (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Pain During Treatment (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.92"/>
                    <measurement group_id="O2" value="-2.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Pain (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Pain (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.88"/>
                    <measurement group_id="O2" value="-2.2" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Reduction in BPI Average Pain at Week 2</title>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Reduction in BPI Average Pain at Week 2</title>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Reduction in BPI Average Pain at Week 6</title>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Reduction in BPI Average Pain at Week 6</title>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Reduction in BPI Average Pain at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Reduction in BPI Average Pain at Week 12</title>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain During Treatment (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the pain at week 2 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain During Treatment (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the pain at week 2 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.34"/>
                    <measurement group_id="O2" value="-1.0" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the pain at week 6 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the pain at week 6 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.27"/>
                    <measurement group_id="O2" value="-1.7" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain During Treatment (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the pain at week 12 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain During Treatment (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the pain at week 12 minus the pain at baseline. The BPI pain ranges from 0 (no pain) to 10 (pain as bad as the patient can imagine).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.6"/>
                    <measurement group_id="O2" value="-1.5" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="33.87"/>
                    <measurement group_id="O2" value="18.0" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="37.3"/>
                    <measurement group_id="O2" value="31.7" spread="45.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The relief of pain ranges from 0% (no relief) to 100% (complete relief).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="35.85"/>
                    <measurement group_id="O2" value="22.9" spread="33.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.5"/>
                    <measurement group_id="O2" value="-1.1" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.89"/>
                    <measurement group_id="O2" value="-2.5" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="2.53"/>
                    <measurement group_id="O2" value="-2.7" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.3"/>
                    <measurement group_id="O2" value="-1.5" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.4"/>
                    <measurement group_id="O2" value="-3.1" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Mood (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.68"/>
                    <measurement group_id="O2" value="-3.0" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.03"/>
                    <measurement group_id="O2" value="-1.0" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.55"/>
                    <measurement group_id="O2" value="-2.1" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.86"/>
                    <measurement group_id="O2" value="-2.4" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.76"/>
                    <measurement group_id="O2" value="-0.1" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.47"/>
                    <measurement group_id="O2" value="-1.3" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.89"/>
                    <measurement group_id="O2" value="-1.8" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.68"/>
                    <measurement group_id="O2" value="-0.1" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.64"/>
                    <measurement group_id="O2" value="-1.7" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.42"/>
                    <measurement group_id="O2" value="-1.7" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.21"/>
                    <measurement group_id="O2" value="-1.0" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.50"/>
                    <measurement group_id="O2" value="-1.5" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.53"/>
                    <measurement group_id="O2" value="-1.9" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.06"/>
                    <measurement group_id="O2" value="-0.6" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.52"/>
                    <measurement group_id="O2" value="-2.2" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.93"/>
                    <measurement group_id="O2" value="-2.1" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression - Improvement (PGI-I) at Week 2</title>
        <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression - Improvement (PGI-I) at Week 2</title>
          <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.01"/>
                    <measurement group_id="O2" value="3.2" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression - Improvement (PGI-I) at Week 6</title>
        <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression - Improvement (PGI-I) at Week 6</title>
          <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.87"/>
                    <measurement group_id="O2" value="2.5" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression - Improvement (PGI-I) at Week 12</title>
        <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression - Improvement (PGI-I) at Week 12</title>
          <description>The investigator judged the improvement of the patient's global impression during treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.35"/>
                    <measurement group_id="O2" value="2.7" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.61"/>
                    <measurement group_id="O2" value="-3.1" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="5.93"/>
                    <measurement group_id="O2" value="-7.3" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="6.02"/>
                    <measurement group_id="O2" value="-7.8" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.23"/>
                    <measurement group_id="O2" value="-1.2" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HADS Anxiety Total Score From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HADS Anxiety Total Score From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.98"/>
                    <measurement group_id="O2" value="-2.2" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HADS Anxiety Total Score From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HADS Anxiety Total Score From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS anxiety total score ranges from 0 (no anxiety) to 21 (extreme anxiety).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.03"/>
                    <measurement group_id="O2" value="-3.3" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HADS Depression Total Score From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HADS Depression Total Score From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.65"/>
                    <measurement group_id="O2" value="-1.6" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HADS Depression Total Score From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HADS Depression Total Score From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.80"/>
                    <measurement group_id="O2" value="-3.4" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HADS Depression Total Score From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HADS Depression Total Score From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The HADS depression total score ranges from 0 (no depression) to 21 (extreme depression).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.07"/>
                    <measurement group_id="O2" value="-3.7" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="8.37"/>
                    <measurement group_id="O2" value="-0.0" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of physical health. Values can range from 0 to 100.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="9.64"/>
                    <measurement group_id="O2" value="2.4" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="8.19"/>
                    <measurement group_id="O2" value="5.0" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of mental health. Values can range from 0 to 100.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="10.19"/>
                    <measurement group_id="O2" value="6.0" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6</title>
        <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6</title>
          <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.06"/>
                    <measurement group_id="O2" value="-0.9" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12</title>
        <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12</title>
          <description>Pain-related life interference (with family and marital functioning, work, social activities). The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no interference) to 6 (extreme interference).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.13"/>
                    <measurement group_id="O2" value="-1.0" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6</title>
        <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6</title>
          <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.28"/>
                    <measurement group_id="O2" value="0.5" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12</title>
        <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12</title>
          <description>Appraisal of support received from spouse, family and significant others. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no support) to 6 (very much support).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.54"/>
                    <measurement group_id="O2" value="0.4" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (not at all strong) to 6 (very strong).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (not at all strong) to 6 (very strong).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.34"/>
                    <measurement group_id="O2" value="-1.0" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.39"/>
                    <measurement group_id="O2" value="-1.2" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6</title>
        <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6</title>
          <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.14"/>
                    <measurement group_id="O2" value="0.2" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12</title>
        <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12</title>
          <description>Perceived life control and ability to solve problems and feelings of personal mastery and competence. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no control) to 6 (extreme control).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.10"/>
                    <measurement group_id="O2" value="0.3" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6</title>
        <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6</title>
          <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.01"/>
                    <measurement group_id="O2" value="-0.5" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12</title>
        <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12</title>
          <description>Affective distress, including ratings of depressed mood, irritability, and tension. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (no distress) to 6 (extreme distress).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.00"/>
                    <measurement group_id="O2" value="-0.8" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6</title>
        <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6</title>
          <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.87"/>
                    <measurement group_id="O2" value="-0.7" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12</title>
        <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12</title>
          <description>Degree to which significant others display negative responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.73"/>
                    <measurement group_id="O2" value="-0.3" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6</title>
        <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6</title>
          <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.12"/>
                    <measurement group_id="O2" value="-0.2" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12</title>
        <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12</title>
          <description>Degree to which significant others display solicitous responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.10"/>
                    <measurement group_id="O2" value="0.2" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6</title>
        <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6</title>
          <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.35"/>
                    <measurement group_id="O2" value="-0.1" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12</title>
        <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12</title>
          <description>Degree to which significant others display distracting responses to the patient's pain behaviors and complaints. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.19"/>
                    <measurement group_id="O2" value="0.0" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6</title>
        <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6</title>
          <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.24"/>
                    <measurement group_id="O2" value="-0.1" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12</title>
        <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12</title>
          <description>Frequency with which the patient engages in household chores. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.29"/>
                    <measurement group_id="O2" value="-0.1" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6</title>
        <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6</title>
          <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.29"/>
                    <measurement group_id="O2" value="0.3" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12</title>
        <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12</title>
          <description>Frequency with which the patient engages in outdoor work. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="10.24"/>
                    <measurement group_id="O2" value="0.6" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6</title>
        <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6</title>
          <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.80"/>
                    <measurement group_id="O2" value="0.1" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12</title>
        <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12</title>
          <description>Frequency with which the patient engages in social activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.64"/>
                    <measurement group_id="O2" value="0.3" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6</title>
        <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6</title>
          <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 6 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.66"/>
                    <measurement group_id="O2" value="0.1" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12</title>
        <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12</title>
          <description>Frequency with which the patient engages in general activities. The change from baseline reflects the week 12 value minus the baseline value. The scores range from 0 (never) to 6 (very frequently).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.73"/>
                    <measurement group_id="O2" value="0.3" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.96"/>
                    <measurement group_id="O2" value="-0.4" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.02"/>
                    <measurement group_id="O2" value="-0.8" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression - Severity Pain From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The score of the Clinical global impression ranges from 1 (not ill at all) to 7 (extremely ill).</description>
          <units>Scores of a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.08"/>
                    <measurement group_id="O2" value="-1.0" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Depression Score From Baseline to Week 2</title>
        <description>The change from baseline reflects the week 2 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Score From Baseline to Week 2</title>
          <description>The change from baseline reflects the week 2 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.50"/>
                    <measurement group_id="O2" value="-4.5" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Depression Score From Baseline to Week 6</title>
        <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Score From Baseline to Week 6</title>
          <description>The change from baseline reflects the week 6 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores of a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.89"/>
                    <measurement group_id="O2" value="-9.3" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Depression Score From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Score From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. A lower score corresponds to a lower level of depression. The score ranges from 0 to 52.</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.30"/>
                    <measurement group_id="O2" value="-9.7" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts by BDI-II at Week 2</title>
        <time_frame>Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts by BDI-II at Week 2</title>
          <population>All patients receiving at least one dose of study medication and having data at week 2.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like to kill myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kill myself if chance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts by BDI-II at Week 6</title>
        <time_frame>Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts by BDI-II at Week 6</title>
          <population>All patients receiving at least one dose of study medication and having data at week 6.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like to kill myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kill myself if chance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts by BDI-II at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts by BDI-II at Week 12</title>
          <population>All patients receiving at least one dose of study medication and having data at week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of killing myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like to kill myself</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kill myself if chance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 2</title>
        <time_frame>Week 2</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 2</title>
          <population>All patients receiving at least one dose of study medication and having data at week 2.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feels life is not worth living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of possible death to self</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideas or gestures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attempts at suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 6</title>
        <time_frame>Week 6</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 6</title>
          <population>All patients receiving at least one dose of study medication and having data at week 6.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feels life is not worth living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of possible death to self</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideas or gestures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attempts at suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication and having data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidal Thoughts or Behaviours by HAMD-17 at Week 12</title>
          <population>All patients receiving at least one dose of study medication and having data at week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feels life is not worth living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of possible death to self</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideas or gestures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attempts at suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Fasting Blood Glucose From Baseline at Week 12</title>
        <description>Ancova analysis controlling for baseline and insulin intake</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication and having data of fasting blood glucose at baseline and at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Fasting Blood Glucose From Baseline at Week 12</title>
          <description>Ancova analysis controlling for baseline and insulin intake</description>
          <population>All patients receiving at least one dose of study medication and having data of fasting blood glucose at baseline and at week 12.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="-12.0" upper_limit="41.8"/>
                    <measurement group_id="O2" value="13.0" lower_limit="-37.7" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12</title>
        <description>Ancova analysis controlling for baseline and insulin intake</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication and having data of HbA1c at baseline and at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12</title>
          <description>Ancova analysis controlling for baseline and insulin intake</description>
          <population>All patients receiving at least one dose of study medication and having data of HbA1c at baseline and at week 12.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Systolic Blood Pressure From Baseline at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Systolic Blood Pressure From Baseline at Week 12</title>
          <population>All patients receiving at least one dose of study medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="16.04"/>
                    <measurement group_id="O2" value="-2.8" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Diastolic Blood Pressure From Baseline at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Diastolic Blood Pressure From Baseline at Week 12</title>
          <population>All patients receiving at least one dose of study medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="10.03"/>
                    <measurement group_id="O2" value="-0.6" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Pulse Rate From Baseline at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Major Depressive Disorder (MDD-)</title>
            <description>Patients with diabetic polyneuropathy and no depression</description>
          </group>
          <group group_id="O2">
            <title>With Major Depressive Disorder (MDD+)</title>
            <description>Patients with diabetic polyneuropathy and depression</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Pulse Rate From Baseline at Week 12</title>
          <population>All patients receiving at least one dose of study medication.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="9.53"/>
                    <measurement group_id="O2" value="2.9" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12</title>
        <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
        <group_list>
          <group group_id="O1">
            <title>MDD- Responder</title>
            <description>MDD-, treatment responder. 60mg Duloxetine (DLX) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MDD+ Responder</title>
            <description>MDD+, treatment responder. 60mg Duloxetine (DLX) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MDD- Non-Responder</title>
            <description>MDD-, not treatment responder. 60mg, after week 5 120mg DLX</description>
          </group>
          <group group_id="O4">
            <title>MDD+ Non-Responder</title>
            <description>MDD+, not treatment responder. 60mg, after week 5 120mg DLX</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12</title>
          <description>The change from baseline reflects the week 12 value minus the baseline value. The BPI average interference score ranges from 0 (pain does not interfere) to 10 (pain completely interferes).</description>
          <population>All patients receiving at least one dose of study medication, having any efficacy data and dosage of duloxetine was not more than 60mg before visit 5</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.65"/>
                    <measurement group_id="O2" value="-2.2" spread="2.0"/>
                    <measurement group_id="O3" value="-0.9" spread="2.5"/>
                    <measurement group_id="O4" value="-2.6" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <desc>12 Weeks treatment period (6 weeks for Treatment Phase 1 and 6 weeks for Treatment Phase 2) and a 2-week taper phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Without Major Depressive Disorder (MDD-)</title>
          <description>Patients with diabetic polyneuropathy and no depression</description>
        </group>
        <group group_id="E2">
          <title>With Major Depressive Disorder (MDD+)</title>
          <description>Patients with diabetic polyneuropathy and depression</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Meddra 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Meddra 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

